WALDENSTROM MACROGLOBULINEMIA

This early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…

This phase 2 study is testing a time-limited combination of three drugs—pirtobrutinib, venetoclax, and rituximab—in 40 patients newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this regimen can achieve a very good partial response o…

This study tests a chemotherapy-free combination of two drugs, venetoclax and rituximab, in people with untreated Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this treatment can achieve deep responses after a fixed 12-month course, avoiding the need…

This study is tracking how well the drug zanubrutinib works and its safety in people with Waldenström macroglobulinemia, a rare blood cancer. Researchers are especially interested in patients with specific genetic mutations and those from racial and ethnic minority groups. The st…

This early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's…

This phase 2 trial tests whether epcoritamab, a type of antibody, can help people with Waldenstrom Macroglobulinemia (a rare blood cancer) that has come back or not responded to prior treatment. The study will enroll 20 participants and measure how many achieve a partial or compl…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This study compares three drug combinations for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 92 participants will receive either ibrutinib plus rituximab, zanubrutinib alone, or venetoclax plus rituximab. The goal is to see which approach lead…

This study tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) in people with Waldenström macroglobulinemia who have not yet received treatment. The goal is to see how many patients achieve a very good partial response or better. About 56 participants w…

This study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…

This study tests a drug called venetoclax in about 14 Japanese adults whose Waldenström macroglobulinemia (a rare blood cancer) has returned or not responded to prior treatment. Participants take venetoclax pills daily, with doses slowly increased to a target level. The goal is t…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study looks at how often high blood pressure happens in people with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. The goal is to see if carefully managing that high blood pressure can reduce the risk of serious he…

This study follows people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), and related conditions to see how these diseases change over time. Participants will have regular check-ups and tests like blood draws and scan…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study looks at how well vaccines work in people with certain blood cancers like chronic lymphocytic leukemia and lymphoma. Researchers will give participants standard vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia, then measure their immune response through…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…

This study is creating a national registry of 1,000 people in Spain diagnosed with Waldenström macroglobulinemia or a related condition (IgM-MGUS) over the past 30 years. Researchers will review medical records to understand patient characteristics, treatments, and outcomes. The …

This study is for people with Waldenström Macroglobulinemia, a rare blood cancer. Researchers want to see if detecting tumor DNA in the blood after 6 months of treatment can predict whether the cancer will come back within 3 years. About 90 participants will provide blood samples…